Humedics Reports Record 2Q Sales of 39.8 Billion KRW... Operating Profit Up 49% YoY

Balanced Growth in Key Businesses Including Aesthetic and CMO

Humedix recorded its highest-ever performance this year by significantly increasing both sales and operating profit in the second quarter.

Humedics Second Factory. [Photo by Humedics]

On the 11th, Humedix announced that its individual sales in the second quarter rose 25% year-on-year to 39.8 billion KRW. Operating profit during the same period also grew by 49%, reaching 11.4 billion KRW. Net profit for the period decreased by 39% compared to the same period last year, recording 3.3 billion KRW.

Humedix explained that it showed balanced growth across all business sectors, including aesthetics centered on Elavie fillers and Liztox, as well as contract manufacturing (CMO).

The aesthetics business saw a significant increase in demand for fillers (Elavie Premier, Revoline) and botulinum toxin (Liztox) at domestic plastic surgery and dermatology clinics due to the COVID-19 endemic effect. Filler exports increased following China's reopening of economic activities, and overseas filler demand surged in Brazil and South America. The CMO business improved its performance due to increased sales of new vial injectables and higher orders for prescription drugs and disposable eye drops.

Operating profit increased as sales growth from the main product lines and order increases significantly improved operating rates and profitability. Net profit decreased due to the reflection of derivative losses on convertible bonds, which did not involve cash outflows.

Humedix plans to continue not only external growth but also profitability improvement in the second half of the year. It aims to maintain growth through strong sales of aesthetic products such as fillers and toxins, expansion of its cosmetics lineup, and the launch of heparin sodium raw material pharmaceuticals.

Jinhwan Kim, CEO of Humedix, stated, "With the COVID-19 endemic improving domestic and international business environments, we showed balanced growth across all business areas, including our core aesthetics and CMO businesses. In the second half, we will secure mid- to long-term growth engines by diversifying overseas markets for fillers and pioneering overseas sales channels for existing products."

This content was produced with the assistance of AI translation services.